Cargando…
The cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in Peru
BACKGROUND: Diabetes mellitus is a public health challenge worldwide, and roughly 25 % of patients with diabetes in developing countries will develop at least one foot ulcer during their lifetime. The gravest outcome of an ulcerated foot is amputation, leading to premature death and larger economic...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623251/ https://www.ncbi.nlm.nih.gov/pubmed/26503154 http://dx.doi.org/10.1186/s12913-015-1141-4 |
_version_ | 1782397659554775040 |
---|---|
author | Cárdenas, María Kathia Mirelman, Andrew J. Galvin, Cooper J. Lazo-Porras, María Pinto, Miguel Miranda, J. Jaime Gilman, Robert H. |
author_facet | Cárdenas, María Kathia Mirelman, Andrew J. Galvin, Cooper J. Lazo-Porras, María Pinto, Miguel Miranda, J. Jaime Gilman, Robert H. |
author_sort | Cárdenas, María Kathia |
collection | PubMed |
description | BACKGROUND: Diabetes mellitus is a public health challenge worldwide, and roughly 25 % of patients with diabetes in developing countries will develop at least one foot ulcer during their lifetime. The gravest outcome of an ulcerated foot is amputation, leading to premature death and larger economic costs. METHODS: This study aimed to estimate the economic costs of diabetic foot in high-risk patients in Peru in 2012 and to model the cost-effectiveness of a year-long preventive strategy for foot ulceration including: sub-optimal care (baseline), standard care as recommended by the International Diabetes Federation, and standard care plus daily self-monitoring of foot temperature. A decision tree model using a population prevalence-based approach was used to calculate the costs and the incremental cost-effectiveness ratio (ICER). Outcome measures were deaths and major amputations, uncertainty was tested with a one-way sensitivity analysis. RESULTS: The direct costs for prevention and management with sub-optimal care for high-risk diabetics is around US$74.5 million dollars in a single year, which decreases to US$71.8 million for standard care and increases to US$96.8 million for standard care plus temperature monitoring. The implementation of a standard care strategy would avert 791 deaths and is cost-saving in comparison to sub-optimal care. For standard care plus temperature monitoring compared to sub-optimal care the ICER rises to US$16,124 per death averted and averts 1,385 deaths. CONCLUSION: Diabetic foot complications are highly costly and largely preventable in Peru. The implementation of a standard care strategy would lead to net savings and avert deaths over a one-year period. More intensive prevention strategies such as incorporating temperature monitoring may also be cost-effective. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12913-015-1141-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4623251 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46232512015-10-28 The cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in Peru Cárdenas, María Kathia Mirelman, Andrew J. Galvin, Cooper J. Lazo-Porras, María Pinto, Miguel Miranda, J. Jaime Gilman, Robert H. BMC Health Serv Res Research Article BACKGROUND: Diabetes mellitus is a public health challenge worldwide, and roughly 25 % of patients with diabetes in developing countries will develop at least one foot ulcer during their lifetime. The gravest outcome of an ulcerated foot is amputation, leading to premature death and larger economic costs. METHODS: This study aimed to estimate the economic costs of diabetic foot in high-risk patients in Peru in 2012 and to model the cost-effectiveness of a year-long preventive strategy for foot ulceration including: sub-optimal care (baseline), standard care as recommended by the International Diabetes Federation, and standard care plus daily self-monitoring of foot temperature. A decision tree model using a population prevalence-based approach was used to calculate the costs and the incremental cost-effectiveness ratio (ICER). Outcome measures were deaths and major amputations, uncertainty was tested with a one-way sensitivity analysis. RESULTS: The direct costs for prevention and management with sub-optimal care for high-risk diabetics is around US$74.5 million dollars in a single year, which decreases to US$71.8 million for standard care and increases to US$96.8 million for standard care plus temperature monitoring. The implementation of a standard care strategy would avert 791 deaths and is cost-saving in comparison to sub-optimal care. For standard care plus temperature monitoring compared to sub-optimal care the ICER rises to US$16,124 per death averted and averts 1,385 deaths. CONCLUSION: Diabetic foot complications are highly costly and largely preventable in Peru. The implementation of a standard care strategy would lead to net savings and avert deaths over a one-year period. More intensive prevention strategies such as incorporating temperature monitoring may also be cost-effective. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12913-015-1141-4) contains supplementary material, which is available to authorized users. BioMed Central 2015-10-26 /pmc/articles/PMC4623251/ /pubmed/26503154 http://dx.doi.org/10.1186/s12913-015-1141-4 Text en © Cárdenas et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Cárdenas, María Kathia Mirelman, Andrew J. Galvin, Cooper J. Lazo-Porras, María Pinto, Miguel Miranda, J. Jaime Gilman, Robert H. The cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in Peru |
title | The cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in Peru |
title_full | The cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in Peru |
title_fullStr | The cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in Peru |
title_full_unstemmed | The cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in Peru |
title_short | The cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in Peru |
title_sort | cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in peru |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623251/ https://www.ncbi.nlm.nih.gov/pubmed/26503154 http://dx.doi.org/10.1186/s12913-015-1141-4 |
work_keys_str_mv | AT cardenasmariakathia thecostofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu AT mirelmanandrewj thecostofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu AT galvincooperj thecostofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu AT lazoporrasmaria thecostofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu AT pintomiguel thecostofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu AT mirandajjaime thecostofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu AT gilmanroberth thecostofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu AT cardenasmariakathia costofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu AT mirelmanandrewj costofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu AT galvincooperj costofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu AT lazoporrasmaria costofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu AT pintomiguel costofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu AT mirandajjaime costofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu AT gilmanroberth costofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu |